An observational study in Cystic Fibrosis, sponsored by University of Portsmouth. Recruiting at 1 site in United Kingdom. Open to participants aged 10 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-18.
Sponsored by University of Portsmouth · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 236 studies in Cystic Fibrosis with a site in United Kingdom — 21 open to participants now, 32 under way, 4 of them phase 3. Cystic Fibrosis · United Kingdom.
Among the 236 studies in Cystic Fibrosis with a site in United Kingdom, this one is the 19th largest by planned enrollment of the 49 observational ones that give a count, is one of 12 that started in 2023, is one of 49 observational ones, reaches primary completion later than 2 of the 31 other live ones, and was the 200th registered.
1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →21 of the 236 studies in Cystic Fibrosis with a site in United Kingdom are open now. Recruiting first, the newest first:
Aimmune Nestlé Health Science US R&D, LLC · Sites in United Kingdom, United States, Bulgaria and 4 more countries
Ages 18–85
Imperial College London · Sites in United Kingdom
Healthy volunteers
University of Nottingham · Sites in United Kingdom
Ages 18–65 · Healthy volunteers
Alexander Horsley · Sites in United Kingdom
Ages 16+
Papworth Hospital NHS Foundation Trust · Sites in United Kingdom
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.
This study: 10 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
236 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 53 · Phase 3 62 · Phase 4 9
First in 2001; this study’s year is marked. 12 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 86 across 504 observational studies indexed under Cystic Fibrosis.
Median enrollment 69 across the 186 interventional studies, 79 across the 49 observational. Of the 186 that completed or were terminated, 83 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
124 of 236 have an industry lead sponsor. The 10 most frequent:
University of Portsmouth is the lead sponsor of 34 studies on the registry; 7 are open to participants now.
University of Portsmouth has 4 studies filed under Cystic Fibrosis — fewer than ten, so there is no comparison to draw.
6 of the studies in Cystic Fibrosis with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
| NCT06237335ReCode TherapeuticsA Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF | 2026-11 |
| NCT07780344University of NottinghamMRI Parameters as Biomarkers in Cystic Fibrosis (FEMPTO) | 2027-05 |
| NCT07879651Royal Brompton & Harefield NHS Foundation TrustSPutum Induction and Nebuliser deviCEs for Patients With CF | 2027-06 |
| NCT07559175Aimmune Nestlé Health Science US R&D, LLCA Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency. | 2027-06 |
Add all 6 to your calendar (.ics) → With an account.
Among the 236 studies in Cystic Fibrosis with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cystic fibrosis (CF) is the most common inherited condition in the United Kingdom, affecting approximately 10,837 people. It is well recognised that regular exercise is clinically important for people with CF. Exercise function measured by the maximal oxygen consumption during a cardiopulmonary exercise test is often reduced in people with CF and this has been attributed to multiple factors including, altered heart and blood vessel function, muscle function, reduced physical activity levels and poorer sleep quality.
New medicine (modulators) have become available for many people with CF. Modulators appear able to reduce sweat chloride concentrations, improve lung function and reduce the frequency of pulmonary exacerbations in people with CF. Little evidence exists to show how they may have changed the fitness and underlying mechanisms responsible for this in people with CF.
This study aims to:
CF is the most common inherited condition in the United Kingdom, affecting approximately 10,837 people. CF affects the movement of salt and water across the body which leads to a thick sticky build up of mucus causing problems in the lungs and digestive system. CF also causes problems in other parts of the body for example, the heart, the blood vessels and muscles. This can impact a person with CFs' ability to exercise which can have impact prognosis, quality of life and increase the amount of times someone with CF is admitted to hospital due to a chest infection.
For many people with CF, new medicine (modulators) have lately become accessible bringing big changes to their health. Elexacaftor-tezacaftor-ivacaftor (ETI) is the most recently approved modulator for use in people with specific CF transmembrane conductance regulator gene mutations and is now the most widely used modulator therapy. So far clinical trials have largely looked at lung function, sweat chloride levels and body mass index. The wider reaching effects of modulator therapy on exercise function has not been studied. This study will see if people with CF have blood vessel and exercise dysfunction, abnormal body composition and reduced physical activity and sleep quality when they are taking modulator therapy compared to a healthy group.
The aims of this study are:
This study will recruit 50 people with CF and 50 healthy age- and sex-matched control participants who are older than 10 years of age. It will ask them to attend the University of Portsmouth for 2 visits. The first visit will last \~3 hours. During this time they will undergo measures on blood vessel function and aerobic exercise function. The second visit will last \~2 hours. During this time they will undergo a body composition scan and a series of muscle function test. At home, participants will wear an accelerometer for 7 days and complete a series of questionnaires.
Participants will be recruited from adult and paediatric CF outpatient clinics within the Southampton CF network.
Inclusion criteria for participants with cystic fibrosis:
Inclusion criteria for healthy control participants:
Exclusion criteria for participants with cystic fibrosis:
Exclusion criteria for healthy control participants:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
No intervention - only assessments.
No intervention - only assessments.
Maximal oxygen uptake
Between group differences in maximal oxygen uptake derived from a maximal cardiopulmonary exercise testing on a cycle ergometer
Time frame: Day 1 - baseline
Peak minute ventilation
Between group differences in peak minute ventilation derived from a maximal cardiopulmonary exercise test on a cycle ergometer
Time frame: Day 1 - baseline
Oxygen uptake at the gas exchange threshold
Between group differences in oxygen uptake at the gas exchange threshold derived from a maximal cardiopulmonary exercise test on a cycle ergometer
Time frame: Day 1 - baseline
Peak power output
Between group differences in peak power output derived from a maximal cardiopulmonary exercise test on a cycle ergometer
Time frame: Day 1 - baseline
Time to exhaustion
Between group differences in time to exhaustion derived from a maximal cardiopulmonary exercise test on a cycle ergometer
Time frame: Day 1 - baseline
Heart rate
Between group differences in heart rate derived from a maximal cardiopulmonary exercise test on a cycle ergometer
Time frame: Day 1 - baseline
Near-infrared spectroscopy derived deoxygenated [haemoglobin + myoglobin]
Between group differences in dynamics of near-infrared spectroscopy derived deoxygenated \[haemoglobin + myoglobin\]
Time frame: Day 1 - baseline
Cardiac output
Between group differences in dynamics of non-invasive thoracic impedance cardiography
Time frame: Day 1 - baseline
Stroke volume index
Between group differences in dynamics of non-invasive thoracic impedance cardiography
Time frame: Day 1 - baseline
Forced Expiratory Volume in the 1st second (% predicted)
Between group differences in Forced Expiratory Volume in the 1st second measured using flow-volume loop spirometry
Time frame: Day 1 - baseline
Forced Vital Capacity (%predicted)
Between group differences in Forced Vital Capacity measured using flow-volume loop spirometry
Time frame: Day 1 - baseline
Total minutes of physical activity (light, moderate, moderate to vigorous physical activity)
Between group differences in physical activity assessed via wrist-worn accelerometery
Time frame: Physical activity will be measured continuously for 7 days
Sleep efficiency (time in bed + time asleep)
Between group differences in sleep efficiency assessed via wrist-worn accelerometery
Time frame: Sleep efficiency will be measured continuously for 7 days
Acetylcholine iontophoresis
Between group differences in acetylcholine iontophoresis measure of microvascular function
Time frame: Day 1 - baseline
Insulin iontophoresis
Between group differences in insulin iontophoresis measure of microvascular function
Time frame: Day 1 - baseline
Percentage change in brachial artery diameter taken from the Flow Mediated Dilation assessment
Between group differences in Flow Mediated Dilation assessment derived from baseline brachial artery diameter and peak brachial artery diameter from flow mediated dilation measure of macrovascular function
Time frame: Day 1 - baseline
Maximum quadricep strength
Derived from a maximal voluntary contraction
Time frame: Day 2 - baseline
Quadricep fatigability index
Derived from change in maximal voluntary contraction
Time frame: Day 2 - baseline
Handgrip strength
Between group difference in handgrip strength
Time frame: Day 2 - baseline
Sit to stand repetitions per minute
Between group difference in sit to stand repetitions per minute
Time frame: Day 2 - baseline
Body composition (total fat-free mass and total fat mass)
Derived from dual-energy X-ray absorptiometry
Time frame: Day 2 - baseline
Habitual activity estimation scale
Between group difference in habitual activity estimation scale - answers are varied and require numerical values, percentages and/or multiple choice questions
Time frame: Day 2 - baseline
Cystic fibrosis questionnaire revised
Between group difference in health related quality of life on a 0 - 100 scale with higher scores indicating better health related quality of life
Time frame: Day 2 - baseline
The Pittsburgh Sleep Quality Index
Between group differences in the Pittsburgh Sleep Quality Index on a 0 - 21 scale with higher scores indicating worse sleep quality
Time frame: Day 2 - baseline
Perceived exertion (breathing effort, chest tightness, throat narrowing, perceived exertion)
Between group differences in perceived exertion using the Dalhousie Dyspnoea and Perceived Exertion Scales during a maximal cardiopulmonary exercise testing on a cycle ergometer on a 1 - 7 scale with a higher value indicating a worse perceived exertion
Time frame: Day 1 - baseline
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2023 (actual). Primary completion is estimated for Feb 2024, 13 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Portsmouth